Immuneering Corporation
Immuneering Corporation is a clinical-stage oncology company dedicated to helping cancer patients live longer and feel better through innovative drug development and biomarker discovery. They utilize proprietary platforms and approaches to develop small molecule drug programs for cancer treatment, with a focus on expanding indications and improving tolerability. The company is involved in various research and development activities, including biomarker discovery, drug response prediction, and leveraging genomic and transcriptomic data to accelerate therapeutic development.
Industries
Nr. of Employees
medium (51-250)
Immuneering Corporation
Cambridge, Massachusetts, United States, North America
Patents
Products
Oral small-molecule MEK inhibitor candidate (deep cyclic MEK inhibitor)
An orally administered, once-daily deep cyclic MEK inhibitor developed for treatment of advanced solid tumors; program is in Phase 2a clinical testing including studies in pancreatic cancer.
Oral small-molecule MEK inhibitor candidate (deep cyclic MEK inhibitor)
An orally administered, once-daily deep cyclic MEK inhibitor developed for treatment of advanced solid tumors; program is in Phase 2a clinical testing including studies in pancreatic cancer.
Services
Collaborative discovery and preclinical development platform focused on orally administered small molecules that modulate signaling dynamics to expand therapeutic windows in oncology.
Services to analyze and integrate public and proprietary genomic/transcriptomic datasets to rank cell lines and preclinical models, identify biomarkers, and generate drug hypotheses.
Collaborative discovery and preclinical development platform focused on orally administered small molecules that modulate signaling dynamics to expand therapeutic windows in oncology.
Services to analyze and integrate public and proprietary genomic/transcriptomic datasets to rank cell lines and preclinical models, identify biomarkers, and generate drug hypotheses.
Expertise Areas
- Clinical trial management for oncology
- Small-molecule oncology drug discovery
- Biomarker discovery and validation
- Integrative bioinformatics and public genomic data mining
Key Technologies
- Genome-wide transcriptomic profiling (microarray/RNA expression analysis)
- Copy number variation and somatic mutation analysis
- Differential expression analysis and batch-correction pipelines
- Pathway enrichment analysis (GSEA) and hierarchical clustering
News & Updates
Discussion of strategies for immune monitoring and biomarker discovery in cancer immunotherapy, in collaboration with the FDA and iSBTc.
Overview of a workshop supported by NCI, iSBTc, and FDA focusing on biomarker discovery and validation in cancer biotherapy.
Analysis of interleukin-6 as a target in ovarian cancer, with insights from recent studies.
Study of transcriptional and cellular signatures in autoimmune diabetes in NOD mice, providing a framework for disease progression markers.
Investigation of gene expression and gene response pathways to optimize antiangiogenic therapies in cancer.
Methods to combine and reuse existing data sets to identify genes and pathways associated with Alzheimer’s, stratify patients, and identify potential therapeutic targets.
Discussion of strategies for immune monitoring and biomarker discovery in cancer immunotherapy, in collaboration with the FDA and iSBTc.
Overview of a workshop supported by NCI, iSBTc, and FDA focusing on biomarker discovery and validation in cancer biotherapy.
Analysis of interleukin-6 as a target in ovarian cancer, with insights from recent studies.
Study of transcriptional and cellular signatures in autoimmune diabetes in NOD mice, providing a framework for disease progression markers.
Investigation of gene expression and gene response pathways to optimize antiangiogenic therapies in cancer.
Methods to combine and reuse existing data sets to identify genes and pathways associated with Alzheimer’s, stratify patients, and identify potential therapeutic targets.